shortage of glp-1 receptor agonists says DHSC Current Insights, Advantages and Challenges

Two of the few recently recognized small molecules that succeeded in entering clinical development, namely LY3502790 and PF-06882961, activate the canonical G protein signaling activity only in the GLP-1 receptor with Trp33 ECD [38,42]

This physiologic effect helps regulate postprandial glucose excursions and contributes to satiety and weight loss

Previously described cardiovascular effects of GLP-1 RAs are primarily indirect and include enhanced endothelial function and myocardial metabolism, natriuresis and anti-inflammatory and blood pressure-lowering effects

3 Johns Hopkins Drug Discovery, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA Correspondence: Soo Kyung Bae, College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, 14662, Republic of Korea, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes